RxDoctor Payments Data

Ankur Sheth, MD

Gastroenterology · Gainesville, GANPI 1396956140

Payments from drug & device makers

$8,051in general payments, 2019–2025

Across 466 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$671
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$591
  • Johnson & Johnson$567
  • Gilead$483
  • Medtronic$449
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,85398%
  • Education$1982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,051 in reported general payments places this provider in the 65th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$187,708
Medicare patients
537
Services billed
5,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide70$57,460
Mesalamine18$7,851
SutabSod Sulf/Pot Chloride/Mag Sulf48$7,697
Sucralfate68$7,319
Mesalamine DrMesalamine12$4,880
Dexlansoprazole DrDexlansoprazole14$2,837
Pantoprazole Sodium253$2,714
Budesonide DrBudesonide28$2,504
Omeprazole253$1,846
Mesalamine ErMesalamine31$1,742
Budesonide EcBudesonide11$1,677
Dicyclomine Hcl101$1,497
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates19$1,357
CholestyramineCholestyramine (With Sugar)31$1,259
Ursodiol24$1,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,075$57,46070 claims
Braintree Laboratories, Inc.Sutab$25$7,69748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →